H.J. Woerle

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

Julio Rosenstock, Ante Jelaska, Cordula Zeller et al. · Diabetes Obesity and Metabolism · 2015 · 257 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( <scp>SGLT2</scp> ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

Julio Rosenstock, Leo Seman, Ante Jelaska et al. · Diabetes Obesity and Metabolism · 2013 · 210 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin ^*

Ulrike Graefe‐Mody, Christian Friedrich, Andreas Port et al. · Diabetes Obesity and Metabolism · 2011 · 185 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

Ramón Gomis, Rosa-Maria Espadero, Russell Jones et al. · Diabetes Obesity and Metabolism · 2011 · 177 citations

Medicine, Pharmacology, Pharmacotherapy +16

Linagliptin (BI 1356), a potent and selective DPP‐4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

Thomas Först, B. Uhlig‐Laske, Arne Ring et al. · Diabetic Medicine · 2010 · 130 citations

Medicine, Pharmacology, Pharmacotherapy +17